Screener
Edgewise Therapeutics, Inc. EWTX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 54,115 | 45,959 |
| Loss from operations | (54,115) | (45,959) |
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
| Net loss | (49,013) | (40,798) |
| Other comprehensive income (loss): | ||
| Unrealized loss on available-for-sale securities, net | (929) | (19) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s interest income?
- Edgewise Therapeutics, Inc. (EWTX) reported interest income of $5.1M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s interest income changed year-over-year?
- Edgewise Therapeutics, Inc.'s interest income decreased by 1.1% year-over-year, from $5.16M to $5.1M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s interest income?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s interest income has grown at a 176.8% compound annual growth rate (CAGR), from $402K to $23.61M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Edgewise Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude